Voya Investment Management LLC Acquires 40,172 Shares of Zymeworks Inc. (NYSE:ZYME)

Voya Investment Management LLC grew its position in shares of Zymeworks Inc. (NYSE:ZYME - Free Report) by 207.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 59,514 shares of the company's stock after buying an additional 40,172 shares during the quarter. Voya Investment Management LLC owned 0.09% of Zymeworks worth $871,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Dimensional Fund Advisors LP lifted its position in Zymeworks by 14.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 972,742 shares of the company's stock valued at $14,240,000 after purchasing an additional 123,240 shares in the last quarter. Assenagon Asset Management S.A. raised its stake in Zymeworks by 93.9% during the 4th quarter. Assenagon Asset Management S.A. now owns 642,251 shares of the company's stock worth $9,403,000 after acquiring an additional 311,107 shares during the period. Walleye Capital LLC purchased a new position in Zymeworks during the fourth quarter valued at approximately $6,629,000. Empowered Funds LLC boosted its position in shares of Zymeworks by 5.1% in the fourth quarter. Empowered Funds LLC now owns 352,753 shares of the company's stock worth $5,164,000 after purchasing an additional 17,092 shares during the period. Finally, Schroder Investment Management Group purchased a new stake in shares of Zymeworks in the fourth quarter worth $4,892,000. 92.89% of the stock is currently owned by hedge funds and other institutional investors.

Zymeworks Price Performance

Shares of NYSE ZYME traded down $0.23 during midday trading on Tuesday, reaching $11.79. 118,228 shares of the stock traded hands, compared to its average volume of 603,145. The company's 50 day moving average is $11.83 and its 200 day moving average is $13.44. Zymeworks Inc. has a one year low of $8.21 and a one year high of $17.70. The stock has a market capitalization of $820.31 million, a PE ratio of -7.86 and a beta of 1.24.

Zymeworks (NYSE:ZYME - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.30) EPS for the quarter, topping analysts' consensus estimates of ($0.45) by $0.15. The business had revenue of $27.11 million during the quarter, compared to analysts' expectations of $20.65 million. Zymeworks had a negative net margin of 182.75% and a negative return on equity of 23.00%. The business's revenue was up 170.3% on a year-over-year basis. During the same period last year, the company posted ($0.42) EPS. As a group, equities analysts forecast that Zymeworks Inc. will post -1.39 EPS for the current year.

Insider Buying and Selling at Zymeworks

In other news, Director Ecor1 Capital, Llc bought 4,397 shares of the stock in a transaction dated Monday, March 31st. The stock was purchased at an average price of $11.75 per share, for a total transaction of $51,664.75. Following the acquisition, the director now owns 17,259,548 shares of the company's stock, valued at $202,799,689. The trade was a 0.03% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders have purchased a total of 1,350,347 shares of company stock worth $16,137,499 over the last ninety days. Company insiders own 1.92% of the company's stock.

Analyst Ratings Changes

Several research analysts recently weighed in on ZYME shares. HC Wainwright upped their target price on shares of Zymeworks from $12.00 to $13.00 and gave the stock a "neutral" rating in a report on Monday, March 10th. Lifesci Capital began coverage on Zymeworks in a research note on Tuesday, March 11th. They issued an "outperform" rating and a $30.00 price objective for the company. Finally, Citigroup boosted their price target on Zymeworks from $18.00 to $19.00 and gave the stock a "buy" rating in a report on Friday, March 7th. Two investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Zymeworks currently has an average rating of "Moderate Buy" and a consensus price target of $21.00.

Zymeworks Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.